Upperton Pharma Solutions, the contract development and manufacturing organisation (CDMO), has completed the build of its new sterile manufacturing facility in Nottingham.
The new 7,000 sq ft facility is in addition to its existing 50,000 sq ft facility, Trent Gateway.
The expansion is a natural progression for Upperton which already develops and manufactures small molecule and biological, non-sterile, oral, nasal and pulmonary dosage forms from early development to late-stage clinical manufacture for global biotech and pharmaceutical companies.
Nikki Whitfield, Chief Executive Officer at Upperton, said: “We are delighted to complete the build of our sterile facility.
“The combined experience of our leadership team in sterile facility builds and subsequent operations ensures that we are ideally placed as a CDMO partner of choice for small to mid-sized biotech and pharma looking to get into the clinic quickly with fast access to sterile manufacturing services.”
Jon Austwick, Director of Quality and Compliance at Upperton, said: “This expansion illustrates our continued investment in our capabilities to support drug developers to scale and accelerate the path to delivering safe and effective medicines to patients.
“The facility has been built with the highest level of quality and is a testament to our internal teams and build vendor who have worked tirelessly over the past 12 months to bring our vision to life.”
